New Guidance Aims to Enhance the Translation of Cell Therapies

The International Society for Stem Cell Research (ISSCR) is proud to announce the release of Best Practices for the Development of Pluripotent Stem Cell-Derived Cellular Therapies, a comprehensive new resource designed to accelerate the translation of human pluripotent stem cell (PSC)-derived therapies into clinical trials and commercial use.

Developed by leading international experts in cell therapy, this groundbreaking document outlines the key principles and decision points required to develop safe, effective, and regulatory compliant PSC-derived products. Organized into seven sections, the guidance offers jurisdictionally neutral information on topics ranging from PSC line selection and raw material use to regulatory considerations, preclinical studies, and clinical trials.